A comprehensive life sciences strategy that reflects the regulatory, market and other needs of the sector is needed to make Canada a more attractive and globally competitive place for investment to ensure a more robust and resilient domestic industry. [...] More attention and support must also be given to the challenges facing the generic medicines sector which provides the vast majority of the medicines used every day to treat Canadians suffering from COVID-19 and so many other critical ailments. [...] In June 2020 CGPA released its Blueprint for a Sustainable Supply of Prescription Medicines for Canadians, which identifies measures to enhance Canada’s existing pharmaceutical manufacturing capacity and domestic capabilities, create a more resilient pharmaceutical supply chain, ensure Canada’s role within a well-functioning global supply chain, and encourage the establishment of a more coordinate. [...] The COVID-19 pandemic has served as a wake-up call for governments, health-care professionals and the broader public on the importance of having a robust and resilient domestic pharmaceutical industry. [...] CGPA and its member companies are committed to working with governments and other stakeholders to apply the lessons that we have learned from the pandemic to make the domestic industry and prescription drug supply chain even stronger and more secure for Canadians.
Authors
- Pages
- 2
- Published in
- Canada
